BlackRock Investment Management, LLC - HTG MOLECULAR DIAGNOSTICS IN ownership

HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H104. A total of 22 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q2 2015. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
BlackRock Investment Management, LLC ownership history of HTG MOLECULAR DIAGNOSTICS IN
ValueSharesWeighting
Q3 2016$60,000
-23.1%
26,521
-7.8%
0.00%
Q2 2016$78,000
-32.2%
28,756
-28.3%
0.00%
Q1 2016$115,000
-42.5%
40,097
-12.4%
0.00%
Q4 2015$200,000
-42.7%
45,7930.0%0.00%
Q3 2015$349,000
-31.7%
45,7930.0%0.00%
-100.0%
Q2 2015$511,00045,7930.00%
Other shareholders
HTG MOLECULAR DIAGNOSTICS IN shareholders Q2 2015
NameSharesValueWeighting ↓
Novo Holdings A/S 1,280,185$5,582,0000.54%
Cormorant Asset Management, LP 201,000$876,0000.10%
PUTNAM INVESTMENTS LLC 575,692$2,510,0000.01%
Alyeska Investment Group, L.P. 89,722$391,0000.00%
BLACKROCK ADVISORS LLC 463,200$2,020,0000.00%
Sonora Investment Management, LLC 1,500$7,0000.00%
SECURIAN ASSET MANAGEMENT, INC 14,008$61,0000.00%
MACKENZIE FINANCIAL CORP 29,208$127,0000.00%
Tower Research Capital LLC (TRC) 336$1,0000.00%
MORGAN STANLEY 12$00.00%
View complete list of HTG MOLECULAR DIAGNOSTICS IN shareholders